FDA warns Meta Labs its supplements are unapproved drugs and have serious manufacturing violations.
What happened
FDA inspected Meta Labs' facility from December 8 through December 18, 2025, and reviewed product labels and the website www.metalabsinc.com in April 2026. FDA found disease-treatment claims that make several supplements unapproved new drugs and misbranded drugs, plus violations of Current Good Manufacturing Practice (CGMP) in finished product specifications, component specifications, master and batch manufacturing records, and laboratory controls. The firm had not responded to the Form FDA 483 (inspection observations) issued at the inspection.
What FDA found
The products are unapproved new drugs because website and label claims say they cure, mitigate, treat, or prevent diseases such as diabetes, viral infections, asthma, and heart disease.
section 201(g)(1)(B), 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d), 505(a) [21 U.S.C. 331(d), 355(a)]The products are misbranded because they lack adequate directions for use for diseases that are not suitable for self-treatment without a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5The company did not establish finished product specifications for identity, purity, strength, composition, and contamination limits for Diabetic Advantage and Respiratory Response.
21 CFR 111.70(e); 21 CFR 111.75(c)The company did not establish component identity specifications and purity, strength, composition, and contamination specifications for all dietary ingredients used.
21 CFR 111.70(b); 21 CFR 111.75(a)Master manufacturing records and batch production records for Diabetic Advantage and Respiratory Response lacked required details such as ingredient identity and weight, theoretical yield, packaging description, process specifications, cleaning times, yield results, quality review documentation, and label quantities.
21 CFR 111.205(b)(1), 111.210, 111.255(b), 111.260The company did not establish and follow quality-control laboratory processes for selecting reference materials, because it compared each finished product against the most recently manufactured batch.
21 CFR 111.315(d)
What FDA wants
FDA asks the company to respond in writing within 15 working days describing specific corrective steps, with documentation and plans to prevent recurrence, or explain why it believes it is not in violation. If corrections cannot be completed in that time, the company must state the reason and when it will finish.
Who should pay attention
- dietary supplement brands using contract manufacturers
- retailers and distributors selling supplement products with disease claims
- quality teams managing supplement CGMP records and supplier specifications
This is a summary. Read the original letter on fda.gov.